U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07368855) titled 'GLP-1 Medicines and Mental Health Changes' on Jan. 20.
Brief Summary: Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life?
Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality.
Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that thes...